Chris Garabedian (Forge Biologics)

Chris Garabe­di­an's first Xon­toge­ny com­pa­ny, Lan­dos Bio­phar­ma, preps a nine-fig­ure IPO as lead pro­gram heads to PhI­II

Lan­dos Bio­phar­ma, the lead com­pa­ny in the port­fo­lio of Chris Garabe­di­an’s fund with Per­cep­tive, is prepar­ing to go pub­lic about a year and a half since its last raise. But the com­pa­ny’s last da­ta dump missed on all its pri­ma­ry end­points in IBD de­spite “pos­i­tive” signs it mea­sured up with stan­dard of care — will in­vestors be im­pressed?

The for­mer Vir­ginia Tech spin­out filed for a $100 mil­lion IPO late Wednes­day, aim­ing to take its AI-based pre­ci­sion med­i­cine plat­form and lead pro­gram to Nas­daq. Once the biotech prices, it will trade on the tick­er $LABP.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.